drugset / Trial / NCT02102516
SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of postoperative administration of SPRIX in pediatric patients (ages 0-11) undergoing open surgical procedures.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-06
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketorolac | Other / unclassified | 3.15 mg | Intranasal |
| Subject | Ketorolac | Other / unclassified | 5.25 mg | Intranasal |
| Subject | Ketorolac | Other / unclassified | 10.5 mg | Intranasal |
| Subject | Ketorolac | Other / unclassified | 15.75 mg | Intranasal |
| Subject | Ketorolac | Other / unclassified | 31.5 mg | Intranasal |
Indications
No indication recorded.